EA200400565A1 - CONJUGATES OF CHEMICALLY MODIFIED HUMAN GROWTH HORMONE - Google Patents

CONJUGATES OF CHEMICALLY MODIFIED HUMAN GROWTH HORMONE

Info

Publication number
EA200400565A1
EA200400565A1 EA200400565A EA200400565A EA200400565A1 EA 200400565 A1 EA200400565 A1 EA 200400565A1 EA 200400565 A EA200400565 A EA 200400565A EA 200400565 A EA200400565 A EA 200400565A EA 200400565 A1 EA200400565 A1 EA 200400565A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chemically modified
growth hormone
human growth
modified human
conjugates
Prior art date
Application number
EA200400565A
Other languages
Russian (ru)
Other versions
EA008505B1 (en
Inventor
Рори Ф. Финн
Уэй Лэйо
Нед Р. Сиджел
Original Assignee
Фармация Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Корпорейшн filed Critical Фармация Корпорейшн
Publication of EA200400565A1 publication Critical patent/EA200400565A1/en
Publication of EA008505B1 publication Critical patent/EA008505B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Abstract

Согласно настоящему изобретению предложен химически модифицированный гормон роста человека (hGH), полученный путем связывания водорастворимого полимера с белком. Химически модифицированный белок по настоящему изобретению может иметь намного более продолжительную активность hGH, чем активность немодифицированного hGH, что дает возможность снизить дозу и создать благоприятные условия режима введения.Отчет о международном поиске был опубликован 2003.08.21.According to the present invention, a chemically modified human growth hormone (hGH), obtained by binding a water-soluble polymer to a protein, is proposed. The chemically modified protein of the present invention may have a much longer activity of hGH than the activity of unmodified hGH, which makes it possible to reduce the dose and create favorable conditions for the administration regime. The international search report was published 2003.08.21.

EA200400565A 2001-11-20 2002-11-20 Chemically modified human growth hormone conjugates EA008505B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (2)

Publication Number Publication Date
EA200400565A1 true EA200400565A1 (en) 2005-06-30
EA008505B1 EA008505B1 (en) 2007-06-29

Family

ID=23295870

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200700431A EA200700431A1 (en) 2001-11-20 2002-11-20 CONJUGATES OF CHEMICALLY MODIFIED HUMAN GROWTH HORMONE
EA200400565A EA008505B1 (en) 2001-11-20 2002-11-20 Chemically modified human growth hormone conjugates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200700431A EA200700431A1 (en) 2001-11-20 2002-11-20 CONJUGATES OF CHEMICALLY MODIFIED HUMAN GROWTH HORMONE

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20050044858A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA200700431A1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
EP1507755A4 (en) * 2001-12-11 2006-05-17 Sun Bio Inc Novel monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
UA82184C2 (en) * 2002-01-18 2008-03-25 Байоджин Айдек Ма Инк. Polyalkylene glycol with residue for conjugation of bioactive compound
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
EA200500475A1 (en) 2002-09-09 2005-10-27 Нектар Терапеутикс Ал, Корпорейшн WATER-SOLUBLE POLYMERIC ALCANALS
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
WO2005034988A1 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Long-acting molecules in sustained release formulations
WO2005070468A2 (en) * 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
EA200700380A1 (en) * 2004-08-31 2007-10-26 Фармация Энд Апджон Компани Ллс CONJUGATES OF GLYCEROLICOLORBED POLYETHYLENE GLYCOL - HUMAN GROWTH HORMONE, METHOD OF THEIR PRODUCTION AND METHODS OF THEIR APPLICATION
MX2007007591A (en) * 2004-12-22 2007-07-25 Ambrx Inc Methods for expression and purification of recombinant human growth hormone.
JP2008525473A (en) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド Modified human growth hormone
JP5425398B2 (en) 2004-12-22 2014-02-26 アンブレツクス・インコーポレイテツド Compositions comprising unnatural amino acids and polypeptides, methods relating to unnatural amino acids and polypeptides, and uses of unnatural amino acids and polypeptides
US20090105134A1 (en) 2005-02-10 2009-04-23 Novo Nordisk A/S C-Terminally Pegylated Growth Hormones
KR20080013878A (en) 2005-04-18 2008-02-13 노보 노르디스크 에이/에스 Il-21 variants
CA2620638A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
ATE500215T1 (en) 2005-11-08 2011-03-15 Ambrx Inc ACCELERATOR FOR THE MODIFICATION OF NON-NATURAL AMINO ACIDS AND NON-NATURAL AMINO ACID POLYPEPTIDES
CN101448512B (en) 2005-12-14 2015-11-25 Ambrx公司 Purposes containing alpha-non-natural amino acid and the compositions of polypeptide, the method relating to alpha-non-natural amino acid and polypeptide and alpha-non-natural amino acid and polypeptide
US9175061B2 (en) 2006-07-07 2015-11-03 Novo Nordisk Health Care Ag Protein conjugates and methods for their preparation
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
JP2010507382A (en) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ IL-21 mutant
CL2008002399A1 (en) 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
EP2272875B1 (en) * 2008-04-03 2014-01-15 Biosteed Gene Expression Tech. CO., LTD. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human growth hormone derivative linked with polyethyleneglycol, method for the preparation thereof and pharmaceutical composition comprising the same
EA020347B1 (en) * 2008-07-31 2014-10-30 Фармаиссэншиа Корп. Peptide-polymer conjugates
KR20110039348A (en) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Conjugated proteins with prolonged in vivo efficacy
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
EP2331139B1 (en) * 2008-09-11 2019-04-17 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
CA2747825A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
CN102612376A (en) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 Growth hormones with prolonged in-vivo efficacy
SG181648A1 (en) 2009-12-15 2012-07-30 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier
JP5980689B2 (en) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Stable growth hormone compound
RU2605627C2 (en) 2010-01-22 2016-12-27 Ново Нордиск Хелс Кеа Аг Growth hormones with prolonged efficacy in vivo
WO2011146518A2 (en) * 2010-05-17 2011-11-24 Cebix Inc. Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
CN105120887A (en) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 Growth hormone compound formulation
WO2016073825A1 (en) 2014-11-06 2016-05-12 Pharmaessentia Corporation Dosage regimen for pegylated interferon
AU2016228555B2 (en) * 2015-03-11 2021-12-23 Nektar Therapeutics Conjugates of an IL-7 moiety and a polymer
KR102443831B1 (en) * 2015-09-18 2022-09-15 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 Long-acting adrenomedullin derivative
CN114539384A (en) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 Pegylated long-acting growth hormone, and preparation method and medical application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ES2113354T3 (en) * 1990-05-04 1998-05-01 American Cyanamid Co STABILIZATION OF SOMATOTROPINS AND OTHER PROTEINS BY MODIFICATION OF CYSTEINE WASTE.
JPH06506217A (en) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE122006000003I2 (en) * 1995-09-21 2011-01-13 Genentech Inc VARIANTS OF HUMAN GROWTH HORMONE
EP1012184B1 (en) * 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
EP1144613B2 (en) * 1999-01-14 2020-05-06 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
DE60004172T2 (en) * 1999-01-29 2004-04-22 F. Hoffmann-La Roche Ag GCSF CONJUGATE
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
AU2002219021A1 (en) * 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds

Also Published As

Publication number Publication date
HUP0500997A2 (en) 2007-11-28
OA13063A (en) 2006-11-10
HRP20040448A2 (en) 2006-02-28
ZA200403907B (en) 2007-12-27
KR20050044858A (en) 2005-05-13
CA2467731A1 (en) 2003-05-30
RS53104A (en) 2006-10-27
AU2002356990A1 (en) 2003-06-10
CO5580794A2 (en) 2005-11-30
NO20042182L (en) 2004-08-11
WO2003044056A2 (en) 2003-05-30
JP2006321808A (en) 2006-11-30
CN1608079A (en) 2005-04-20
EP1453859A2 (en) 2004-09-08
GEP20063860B (en) 2006-06-26
MA27544A1 (en) 2005-10-03
PL374354A1 (en) 2005-10-17
IL162031A0 (en) 2005-11-20
AP2004003050A0 (en) 2004-06-30
BR0214451A (en) 2006-05-30
KR20070072924A (en) 2007-07-06
EA008505B1 (en) 2007-06-29
WO2003044056A3 (en) 2003-08-21
IS7268A (en) 2004-05-17
EA200700431A1 (en) 2008-02-28
MXPA04004809A (en) 2004-08-11
JP2005525302A (en) 2005-08-25
TNSN04090A1 (en) 2006-06-01
ECSP045114A (en) 2004-07-23

Similar Documents

Publication Publication Date Title
EA200400565A1 (en) CONJUGATES OF CHEMICALLY MODIFIED HUMAN GROWTH HORMONE
DK1715887T3 (en) N-terminal Monopegylated Human Growth Hormone Conjugates, Methods for their Preparation and Use
EA200300856A1 (en) LONG-LIVATING DERIVATIVES OF THE GROWTH HORMONE REHEADING FACTOR
EP2829549A3 (en) Hybrid and tandem expression of neisserial derived proteins
CY1107146T1 (en) METHODS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE (AD)
EA200300381A1 (en) NUCLEIC ACIDS AND POLYPEPTIDES OF THE NEW RECEPTOR
CY1107628T1 (en) HUMAN CTLA-4 ANTIBODIES AND USES
CY1109786T1 (en) METHODS FOR THERAPEUTIC TREATMENT OF RHEUMATIC DISEASES USING A SOLUBLE CTLA4 MOLECULE
EA200201214A1 (en) SUBSTITUTED THYOCETAMIDES
BR0208183A (en) Peptide modified by wt1
EA199900979A1 (en) COMPOSITIONS OF ACTIVATED PROTEIN
BRPI0513959A (en) antibodies directed against beta-amyloid peptide, their pharmaceutical compositions, kit and methods of manufacture thereof
RU2009105696A (en) N-END POLYSIAL
CY1107584T1 (en) METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF ANIMALS
JP2005527470A5 (en)
DE60140426D1 (en) PHARMACEUTICAL COMPOSITION FOR MUSCLE ANABOLISM
EP2279752A3 (en) Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation
MXPA04000599A (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation.
EA200100905A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PROTONE PUMP INHIBITORS
MXPA05004993A (en) Chemically-modified human growth hormone conjugates.
EP1891954A3 (en) Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
DK1007566T3 (en) Therapeutic use of SMR1 protein and its active derivatives
EP2962699A3 (en) Improved method for preparing conjugates of proteins and chelating agents
TW200501963A (en) Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
EA200400392A1 (en) BINDING KASPAZU-8 PROTEIN, ITS OBTAINING AND APPLICATION